NASDAQ:FOLD

Amicus Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FOLD

*Your capital is at risk

$14.49

+0 (+0%)

At Close: Jun 03, 2026

Amicus Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 6.53M FOLD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	6.53M shares
0% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Apr 27, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	18 574 Value: $237.9K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	19 473 Value: $233.7K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	16 236 Value: $139.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Wheeler Craig A Director	Director	30 000 Value: $201.3K
Apr 27, 2026 Sell	Common Stock D-Return	Wheeler Craig A Director	Director	84 631 Value: $1.23M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	55 203 Value: $658.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	43 592 Value: $620.8K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	62 715 Value: $590.1K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Castelli Jeff Chief Development Officer	Officer	82 644 Value: $829.7K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Raab Michael Director	Director	16 236 Value: $139.6K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Clark David Michael Chief People Officer	Officer	77 134 Value: $774.4K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Clark David Michael Chief People Officer	Officer	84 842 Value: $1.09M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Castelli Jeff Chief Development Officer	Officer	150 517 Value: $1.42M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Clark David Michael Chief People Officer	Officer	91 439 Value: $873.2K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Clark David Michael Chief People Officer	Officer	105 388 Value: $1.26M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Rosenberg Ellen Chief Legal Officer	Officer	108 980 Value: $1.55M
Apr 27, 2026 Sell	Common Stock D-Return	Rosenberg Ellen Chief Legal Officer	Officer	15 000 Value: $217.5K
Apr 27, 2026 Sell	Common Stock D-Return	Clark David Michael Chief People Officer	Officer	221 811 Value: $3.22M
Apr 27, 2026 Sell	Common Stock D-Return	Castelli Jeff Chief Development Officer	Officer	427 089 Value: $6.19M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	37 810 Value: $457.9K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	3 176 Value: $31.9K
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Prout Samantha Chief Accounting Officer	Officer	2 526 Value: $24.1K
Apr 27, 2026 Sell	Common Stock D-Return	Prout Samantha Chief Accounting Officer	Officer	125 951 Value: $1.83M
Apr 27, 2026 Sell	Stock Options (right to buy) D-Return	Rosenberg Ellen Chief Legal Officer	Officer	203 825 Value: $1.92M
Apr 27, 2026 Sell	Common Stock D-Return	Harford Simon N.r. Chief Financial Officer	C-Suite Officer	143 595 Value: $2.08M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AMICUS THERAPEUTICS

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym...

Read Full Profile Here